DNAL4

Across TCGA pan-cancer cohorts, DNAL4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAL4 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAL4 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where DNAL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.256	0.510	.005	22	view →
LUAD	DFS	Median	All	0.462	0.874	.006	9	view →
LSCC	DFS	Tertile	All	0.437	1.000	.006	9	view →
GBM	DFS	Tertile	All	0.625	0.291	.017	7	view →
HNSC	OS	Median	IV	0.569	0.807	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAL4–PDAC (DFS)

Open the PDAC breakdown →